Intrinsiqq

Clínica Baviera, S.A. (CBAV.XMAD) Quality Score

CBAV.XMAD
Quality75

Valuation remains strong (avg 90/100), but business quality is pulling the composite down (avg 73/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
90/100
18.6x

Under 20x, reasonable relative to earnings

Cash Flow Multiple
90/100
18.8x

Under 20x cash flow, well covered

Revenue Growth
100/100
12.4%

Above 10% CAGR, strong compounder

Cash Flow Growth
50/100
4.2%

2–5% CAGR, growing but slowly

Business Quality & Capital Allocation

Share Dilution
80/100
-1.7%

Roughly flat, no meaningful dilution

Margin Trend
20/100
-0.8pp

Modest contraction, within normal range

Capital Structure
90/100
€20M

Net debt/FCF of 0.4x, easily serviceable

2022
€39M
€48M
2023
€51M
€47M
2024
€39M
€63M
2025
€50M
€71M
Return on Capital
100/100
25.2%

Above 20%, exceptional capital efficiency

Customize WeightsPremiumUpgrade

Clínica Baviera (CBAV.XMAD) quality: score, margins and returns

Clínica Baviera (CBAV.XMAD) scores 75/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 20.4% operating margins and 25.2% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is Clínica Baviera (CBAV.XMAD) a high-quality business?+

Clínica Baviera scores 75 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 20.4% operating margin and a 25.2% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Clínica Baviera's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from CBAV.XMAD's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Clínica Baviera scores well and where it falls behind.

What is Clínica Baviera's return on invested capital (ROIC)?+

Clínica Baviera earns about 25.2% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to CBAV.XMAD's margins and growth on this scorecard to judge durability.

How profitable is Clínica Baviera?+

Clínica Baviera runs an operating margin of about 20.4% and a net margin of about 14.8%. Revenue has grown at roughly 15.0% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

More on CBAV.XMAD: Overview · DCF valuation · Dividend safety · Financials
How the market compares: US profitability statistics

Related stocks: Diagnostics & Research

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.